North America Epigenetics Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents and Kits, Enzymes, Software, Service), By Applications (Oncology, Autoimmune Diseases, Metabolic Diseases, CNS/Pain Diseases, Cardiovascular Diseases, Others), By End-User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations (CROS), Others) and By Country(U.S., Canada) Forecasts, 2024-2032

Market Overview

The North American epigenetics market size was valued at USD 760.79 million in 2023. It is estimated to reach USD 2,848.66 million by 2032, growing at a CAGR of 15.80% during the forecast period (2024–2032). The epigenetics market for North America is primarily driven by the rising cases of chronic diseases, specifically cancer, due to the adoption of unhealthy lifestyle choices such as smoking, poor diet, lack of exercise, and excessive alcohol consumption in this region. Moreover, the region is a hub for advancements in epigenetics by the prominent regional market players, thereby creating opportunities for market growth.

Market Dynamics

North america epigenetics market drivers:

Rising prevalence of cancer 

The increasing prevalence of cancer in North America is a significant driver for the growth of the epigenetics market. Cancer remains a primary cause of morbidity and mortality in the region, with a rising incidence observed across various demographics. The American Cancer Society estimated that there would be 1.91 million new cases of cancer diagnosed and 608,570 cancer fatalities in the US in 2021.

Epigenetic alterations are crucial in cancer initiation, progression, and metastasis, offering valuable insights into disease mechanisms and potential therapeutic targets. As researchers delve deeper into understanding the epigenetic landscape of different cancer types, the demand for epigenetics products and services continues to escalate, driving market expansion and innovation in North America's healthcare landscape.

North america epigenetics market restraint:

Complexity of epigenetic mechanisms

Epigenetic mechanisms encompass various events, including non-coding RNA regulation, histone modifications, and DNA methylation. The highly dynamic and interconnected interactions among these systems have an impact on patterns of gene expression. The multitude of combinations and interactions among these systems makes it challenging to pinpoint their precise roles in gene regulation and disease pathways.

The ethical concerns surrounding the study and application of epigenetics also affect the market environment. The ability to modify epigenetic markers raises moral concerns regarding potential adverse impacts, long-term effects on individuals, and social implications. This appropriate and ethical application of epigenetic technology depends on negotiating regulatory frameworks and ethical standards, which can slow down innovation and commercialization. This is estimated to restrict the North American epigenetics market growth.

North america epigenetics market opportunities:

Advancements in epigenetics

The key players in the North American region are developing novel products that are aimed at advancing epigenetics solutions. For instance, in November 2023, FOXO Technologies, a firm specializing in epigenetic biomarker technology based in Minneapolis, announced its intention to launch a direct-to-consumer product. This product will utilize epigenetic data and artificial intelligence. The business asserts that the subscription-based service would deliver individualized health and wellness suggestions using FOXO's machine-learning algorithms to analyze epigenetic biomarkers linked to health results and verified clinical information. This is estimated to create opportunities for the growth of the North American epigenetics market.

Regional Analysis

North America leads the global epigenetics market, driven by robust healthcare infrastructure, extensive research funding, and a strong presence of key industry players. Academic institutions and biotechnology firms in North America actively engage in epigenetic research, contributing to the region's prominence in the field. Similarly, the rising cases of chronic diseases like cancer are further estimated to boost the North American epigenetics market. For instance, according to CMAJ, the projected number of new cancer diagnoses in Canada for 2024 is 247,100, with an anticipated 88,100 cancer-related fatalities. This represents an increase from the estimated 239,100 cancer cases and 86,700 cancer deaths in 2023.

Furthermore, the key regional players are involved in strategic initiatives to enhance the capabilities of epigenetics. For instance, in October 2023, Zenith Epigenetics Ltd., a prominent player in the field of epigenetics, signed a partnership agreement with Cencora (previously known as AmerisourceBergen) with the goal of expediting the commercialization of Zenith Epigenetics' ZEN-3694 program. The ZEN-3694 program is a sophisticated method that combines epigenetics to enhance the effectiveness of cancer treatment using medications that are already available in the market.

Thus, the factors above are anticipated to boost the North American epigenetics market growth.

Segmental Analysis

The North American epigenetics market is segmented by product, application, and end-user.

Based on product, the epigenetics market for North America is divided into instruments, reagents and kits, enzymes, software, and services. 

The reagents and kits segment dominates the global market and is projected to exhibit a CAGR of 16.2% over the forecast period. The reagents and kits segment is a cornerstone of the North American epigenetics market, providing essential tools for epigenetic research and analysis. These products include DNA methylation kits, histone modification antibodies, bisulfite conversion kits, and chromatin immunoprecipitation (ChIP) kits, enabling researchers to study epigenetic modifications with precision and efficiency.

Based on application, the North American epigenetics market is segmented into oncology, autoimmune diseases, metabolic diseases, CNS/pain diseases, cardiovascular diseases, and others. 

The oncology segment is estimated to own the highest market share and grow at a CAGR of 16.0% over the forecast period. Given the critical role of epigenetic modifications in cancer biology, oncology represents a dominant application area in the North American epigenetics market. Epigenetic profiling aids in the identification of cancer subtypes, prognosis prediction, and the development of targeted therapies, fostering personalized treatment approaches and improving patient outcomes.

Based on end-users, the North American epigenetics market is bifurcated into pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROS), and others. 

The pharmaceutical and biotechnology companies contributed to the largest market share and is expected to expand at a CAGR of 16.4% over the forecast period. Pharmaceutical and biotechnology companies are key players in the North American epigenetics market, driving innovation in drug discovery and development. They utilize epigenetic insights to identify novel therapeutic targets, develop epigenetic drugs, and conduct clinical trials, leveraging epigenetic technologies to advance precision medicine approaches.

Recent Developments

• December 2023-Chroma Medicine, Inc., a company specializing in genomic medicine, showcased data at the American Society of Hematology (ASH) 65th Annual Meeting in San Diego. The data presented highlighted the potential of Chroma's multiplex epigenetic editing platform to improve the effectiveness of functional allogeneic chimeric antigen receptor (CAR) T cells.